Journal of Clinical Oncology
Articles in this Issue
Impact of venous thromboembolism on survival in multiple myeloma patients receiving bispecific antibody therapy: Insights from real-world data.
7521 Background: Patients with multiple myeloma (MM) have a significantly higher risk of venous thromboembolism (VTE), up to 20 times greater than the gen...
Bridging the language gap in palliative oncology: A translation and validation of the Urdu version of EORTC’s QLQ-C15-PAL.
e24049 Background: The World Health Organization (WHO) estimates that around 56.8 million people require palliative care each year, while only 7.9 million...
Race, sex, and survival disparities in mycosis fungoides and Sézary syndrome: A SEER8 database analysis (1975–2021).
e19056 Background: Cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), exhibits survival disparities by race and...
The addition of anti-angiogenic agents to chemotherapy and effects on progression free survival in posterior lines for patients with advanced soft tissue sarcoma: A retrospective analysis.
e23539 Background: Soft tissue sarcoma (STS) is one kind of rare and heterogenous tumor with poor prognosis, especially after recurrence or metastasis. Se...
Prognostic factors and prediction of long-term survival in ES-SCLC.
e20114 Background: This study aims to investigate the prognostic factors associated with survival outcomes in patients with extensive-stage small cell lun...
Concomitant treatment with 2nd generation hormone therapy and 177Lut PSMA versus 177Lut PSMA alone: Does it improve PSA response rates?
e17081 Background: Prostate cancer is the most common cancer in men. In early localized disease, surgery represents the mainstay treatment. However, manag...
Subtype-specific trends in lung cancer incidence and survival: A SEER analysis (2004–2021).
1643 Background: Lung cancer remains a leading cause of cancer mortality, with adenocarcinoma, squamous cell carcinoma (SCC), and small cell lung cancer (...
First-line osemitamab (TST001) plus nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102): Updated results of cohort G from a phase I/IIa study.
4032 Background: Claudin 18.2 (CLDN18.2) is a clinically validated therapeutic target and has been broadly explored with different modalities in gastric/g...
Real world analysis of VTE incidence in lung cancer: A comprehensive assessment of the Khorana score and other clinical factors in predicting VTE incidence.
e23290 Background: Patients with lung cancer have increased risk of venous thromboembolism (VTE). ASCO guidelines do not support routine VTE prophylaxis b...
Five-year median follow-up update of PURE-01: A phase 2 study of neoadjuvant pembrolizumab followed by radical cystectomy in patients with muscle-invasive bladder cancer (MIBC).
4595 Background: In patients (pts) with MIBC, the PURE-01 study pioneered the use of neoadjuvant immunotherapy by administering 3 courses of pembrolizumab...
Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with chemoradiotherapy for women with locally advanced cervical cancer.
TPS5619 Background: Cervical cancer (CC) is one of the leading cause of death in developing countries, largely due to insufficient HPV vaccination coverag...
The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A real-world study.
e16146 Background: The promising therapeutic outcomes of neoadjuvant immunotherapy with chemotherapy (NAIC) in the treatment of resectable locally advance...
Trends in immune-related adverse event reporting among multidisciplinary cancer programs.
e14529 Background: The Association of Cancer Care Centers’ (ACCC) Immuno-Oncology (IO) Institute provides foundational IO education to multidisciplinary c...
A prospective observational study to compare speech and swallowing outcomes in different types of oral tongue defects and reconstructions in patients undergoing treatment for oral tongue squamous cell carcinoma.
11113 Background: The tongue is an important organ for speech and swallowing functions. Oral tongue squamous cell carcinoma (OTSCC) can per se affect thes...
Comparative analysis of fibroblast activation protein Inhibitor (FAPI) O4 PET/CT versus flurodeoxyglucose (FDG) PET/CT in staging gastrointestinal tumours.
3093 Background: FAPI 04 PET/CT has emerged as a promising alternative to FDG PET/CT, offering potential advantages in sensitivity, specificity, and patie...
From innovation to impact: How new therapies and racial disparities shaped melanoma survival.
e21578 Background: Melanoma remains a significant contributor to cancer-related mortality worldwide. The advent of immunotherapies, beginning with CTLA-4...
Congruence between circulating tumor DNA and radiographic response during treatment of advanced sarcoma patients.
e23531 Background: Imaging assessments remain the standard of care to monitor therapy response or disease recurrence in advanced sarcoma. It remains uncle...
Prognostic factors for survival in advanced epithelial ovarian cancer: A retrospective analysis.
e17604 Background: Approximately 60% of Epithelial Ovarian cancer (EOC) cases are diagnosed at an advanced staged, and 75% of patients experience disease...
Burnout and other causes of physician attrition: A qualitative study of physicians leaving direct patient care.
e21002 Background: The rising rate of physician turnover poses a crisis for both public health and individual patients, including over 18 million cancer s...
Impact of socioeconomic and geographic disparities on early mortality and treatment-related complications in a rural Appalachian cohort with acute promyelocytic leukemia.
e23172 Background: Acute promyelocytic leukemia (APL) is a curable yet aggressive subtype of acute myeloid leukemia (AML) associated with early mortality...
Characterization of histology-dependent immunobiological differences in metastatic NSCLC: Implications for treatment with PD-1 and LAG-3 inhibitors.
8526 Background: The treatment paradigm for metastatic non-small cell lung cancer (mNSCLC) without actionable genomic alterations does not differentiate b...
External beam radiation therapy for salvage after focal therapy as primary treatment in prostate adenocarcinoma.
e17153 Background: Focal therapy (FT) for prostate adenocarcinoma (PCa) aims to minimize adverse effects while achieving tumor control. While FT is becomi...
Characteristics and mortality risk among esophageal cancer patients with varied HIV status seeking care in western Kenya: A 10-year analysis.
e16090 Background: Esophageal cancer (EC) is among the top five prevalent cancers in Africa, including at Jaramogi Oginga Odinga Training and Referral Hos...
Outcomes with trilaciclib versus granulocyte colony stimulating factor regarding chemotherapy-associated adverse events, dose reductions, and subsequent therapies in small cell lung cancer.
e20116 Background: Trilaciclib is a CDK4/6 inhibitor approved for extensive-stage small cell lung cancer (ES-SCLC) as a supportive care medication with pl...
Efficacy and safety of EGFR and VEGF inhibitors in stage II-IV colon cancer: A retrospective analysis using the TriNetX database.
e15656 Background: The use of targeted therapies, including EGFR and VEGF inhibitors, in combination with chemotherapy has revolutionized the treatment of...